AACR & ASCO 2021 – Midyear Review

Dr Mark Socinski reviews a broad variety of studies, including the evolving role of EGFR inhibitors and immunotherapy in NSCLC, the benefits of immunotherapy plus chemotherapy, and the impact of immune-related adverse events on clinical outcomes in NSCLC. Read More ›

Adjuvant atezolizumab extends disease-free survival after adjuvant chemotherapy compared with best supportive care after adjuvant chemotherapy in patients with resected stage II/IIIA non–small-cell lung cancer (NSCLC). Read More ›

Every year, researchers and clinicians report on exciting advancements in the diagnosis and treatment of cancer. In 2021, despite the COVID-19 pandemic, developments in the management of lung cancer continue to be important and intriguing. Read More ›

Combining nivolumab with a limited course of chemotherapy in resectable non–small-cell lung cancer (NSCLC) enhances rates of pathologic complete response compared with chemotherapy alone. Read More ›

Based on results of the RATIONALE 303 trial, tislelizumab significantly prolonged median overall survival by more than 5 months in patients with advanced non–small-cell lung cancer (NSCLC) compared with docetaxel. Read More ›

Resistance to the combination of osimertinib plus savolitinib is predominantly mediated by acquired mutations in either MET, EGFR, or KRAS in patients with EGFR-mutated metastatic non–small-cell lung cancer (NSCLC). Read More ›

In patients with advanced squamous non–small-cell lung cancer (NSCLC), the combination of bintrafusp alfa and chemotherapy was well tolerated. The most common treatment-related adverse events were anemia, nausea, and pruritus. Read More ›

Compared with docetaxel, sintilimab significantly prolonged median overall survival by more than 3 months in patients with advanced squamous non–small-cell lung cancer (NSCLC). Read More ›

In patients with non–small-cell lung cancer and KRAS G12V mutations who were pretreated with chemotherapy and immunotherapy, the combination of VS-6766 and defactinib is active with an acceptable tolerability profile. Read More ›

In patients with non–small-cell lung cancer (NSCLC) that involves the central nervous system and who lack genetic rearrangements or tumor targets, DM-CHOC-PEN, a bis-alkylator of DNA, has produced long-term objective responses with manageable toxicities. Read More ›

Page 1 of 3

Conference Correspondent Coverage is Brought to You by the Publishers of:
American Health & Drug Benefits
Journal of Hematology Oncology Pharmacy
Journal of Oncology Navigation & Survivorship
Oncology Practice Management
Personalized Medicine in Oncology
Value-Based Cancer Care

Learn more about our family of publications.

View Our Publications